Potent Ventures Appoints Mr. Michael Hopkinson as a Corporate Director

Potent Ventures (CSE: POT) (FSE: 0OS2) (OTCQB: POTVF) ("Potent" or the "Company") is excited to announce the appointment of finance and business leader, Mr. Michael Hopkinson as a Corporate Director.


  • Mr. Hopkinson holds the designation of US Certified Public Accountant (CPA)
  • Extensive Experience as Public Company Chief Financial Officer and Senior Leadership Team Strategist
  • Public Accounting Firm Experience with Arthur Andersen LLP, PricewaterhouseCoopers LLP, and Ernst & Young LLP

"We are thrilled to have Mr. Hopkinson join the Potent board of directors. Michael's knowledge and experience will be of great value to the Company as we advance toward product launch," said Mr. Charlie Lamb, Potent President and CEO.

Michael Hopkinson Highlights

  • Mr. Michael Hopkinson is a US Certified Public Accountant (CPA) licensed in the state of New Hampshire.
  • He has extensive corporate and cross border tax compliance and planning expertise, specializing in corporate compliance and planning, with over 20 years of experience.
  • He has developed his skills under such notable public accounting firms as PricewaterhouseCoopers LLP, and Ernst &Young LLP.
  • He has served several public companies as clients and has previous CFO and director experience with TSX-V and CSE listed companies.

"The Company's plans to enter into the low-sugar gummy sector represent a truly compelling model in a high growth sector. I am excited to contribute to support the launch and growth plans to establish the Company as a market leader," said Mr. Hopkinson.

Charlie Lamb, President & CEO, Director
Telephone: 1(236) 317-2812 - Toll free 1(888) 556-9656
E-mail: investors@potent-ventures.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the change of business and regulatory and shareholder approval of same, growth of the low sugar and plant-based gummy market, business strategy, corporate vision, proposed expansion, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition, and results of operations. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

Source

POT:CC
The Conversation (0)
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Reinstatement to Quotation

Description

The suspension of trading in the securities of Radiopharm Theranostics Limited (‘RAD’) will be lifted immediately following the release by RAD of an announcement regarding its capital raising.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Receives Strategic Investment for up to A$18 million

Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Trading Halt

Description

The securities of Radiopharm Theranostics Limited (‘RAD’) will be placed in trading halt at the request of RAD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 24 June 2024 or when the announcement is released to the market.

Keep reading...Show less
Man holds hand to head as fragments break off representing Alzheimer's disease.

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.

According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.

This condition affects more than 6.9 million people in the US alone; it’s also the most common form of dementia and is the seventh leading cause of death in America. Treatments are available to alleviate Alzheimer’s disease symptoms, but because they do not affect the underlying causes of this neurodegenerative disease, they’re only a bandaid solution.

Keep reading...Show less

Latest Press Releases

Related News

×